简介：AIM:Toevaluatetheefficacyandsafetyofacombinedtreatmentformyopicchoroidalneovascularization(CNV)usingphotodynamictherapy(PDT)andintravitrealbevacizumabandtocompareitwithintravitrealbevacizumabmonotherapy.METHODS:Thirty-foureyeswithangiographicevidenceofmyopicCNVwererandomlydividedintotwogroups:17weretreatedwithoneintravitrealbevacizumabinjection(1.25mg)andlow-fluence-ratePDTwithinsevendaysoftheinjection(GroupA).Theother17receivedmonotherapywithbevacizumabinjections(GroupB).Clinicalevidenceofcomplications,bestcorrectedvisualacuity(BCVA)andfluoresceinleakagewereevaluated.BCVAandopticalcoherencetomography(OCT)wereevaluatedmonthly.Thetimepointsfollow-upwasestablishedat6and12mo.AllpatientswereretreatedfollowingaPRNprotocol.RESULTS:Atotalof34eyesof34patients(26womenand8men)withameanageof62.35yearswereincluded.InGroupA(17eyes)themeanBCVAincreasedfrom0.55±0.13logMARbeforethetreatmentto0.40±0.09logMARatthe12mofollow-up(P<0.01).InGroupB(17eyes)themeanBCVAincreasedfrom0.60±0.11logMARbeforethetreatmentto0.55±0.12logMARatthe12mofollow-up(P<0.01).TherewasnostatisticallysignificantdifferencebetweenthetwogroupsintermsofLogMarvisualacuity.InGroupAthemeannumberofcombinedtreatmentswas1.8±0.11perpatient;inGroupBthemeannumberofintravitrealbevacizumabinjectionswas3.1±0.08perpatient.ThenumberoftreatmentswassignificantlyfewerinGroupA(P<0.01).Nolocalorsystemicsideeffectsoccurredamonganyofthepatientstreatedinthisstudy.CONCLUSION:Thecombinationofanti-angiogenicinjectionsandPDTappearstobeasafeandeffectiveoptionformyopicCNVtreatmentandallowsforasignificantreductionofintravitrealinjections.

简介：DearEditor,IamDr.KhayWeiPohfromDepartmentofOphthalmology,HospitalKualaLumpur,Malaysia.IwritetoshareacaseofdiffusechoroidalhaemangiomainachildwithSturgerWebersyndromewhoshowedresolutionofexudativeretinal

简介：

简介：Leber'scongenitalamaurosis(LCA)andrecentgenetherapyadvancementfortreatinginheritedretinopathieswereextensiveliteraturereviewedusingMEDLINE,PubMedandEMBASE.Adeno-associatedviralvectorswerethemostutilisedvectorsforoculargenetherapy.Conephotoreceptorcellsmightuseanalternatepathwaywhichwasnotreliantoftheretinalpigmentepithelium(RPE)derivedretinoidisomerohydrolase(RPE65)toaccessthe11-cisretinaldehydechromophore.Researcheffortsdedicatedontheprogressionofagene-basedtherapyforthetreatmentofLCA2.Suchgenetherapyapproacheswereextremelysuccessfulincanine,porcineandrodentLCA2models.TherecombinantAAV2.hRPE65v2adenoassociatedvectorcontainedtheRPE65cDNAandwasreplicationdeficient.ItsinvitroinjectionintargetcellsinducedRPE65proteinproduction.Thegenetherapytrialsthatweresofarconductedforinheritedretinopathieshavegeneratedpromisingresults.PhaseIclinicaltrialstocureLCAandchoroideremiademonstratedthatadeno-associatedviralvectorscontainingRPEgenesandphotoreceptorsrespectively,couldbesuccessfullyadministeredtoinheritedretinopathypatients.AphaseIIItrialispresentlyongoingandifsuccessful,itwillleadthewaytoadditionalgenetherapyattemptstocuremonogenic,inheritedretinopathies.

简介：为了在长期的绿内障patients.METHODSA评估有中央角膜的subbasal神经纤维层的眼睛的表面变化和它的关联，没有任何眼睛的问题，眼睛的表面评估的未来的比较学习为至少6mo和25个正常题目的50只眼睛在使用二的25个病人或更多的antiglaucoma药的50只眼睛被执行作为控制。评估的学习参数包括了视觉尖酸，intraocular压力，眼睛的表面评估参数[荧光黄分散时间(FTBUT)，我测试的Schirmers，眼睛的表面染色分数和眼睛的表面疾病索引分数(OSDI)]，中央角膜的感觉(CochetBonnettaesthesiometer)，由在绿内障盒子和控制组中的共焦的microscopy.RESULTSThe平均数值的中央subbasal神经纤维层密度(SBNFLD)分别地如下：OSDI分数(35.89祣潴楫敮????????????木????€???€乔????偉?‰??????????倨???‵？？

简介：AIMTo与医学上在开的角度绿内障(OAG)或在医药treatment.METHODSThis学习是的antiglaucoma下面是主要或第二等的OAG病人的回顾的评论的眼睛的高血压(OHT)病人和OHT病人作为附属治疗估计有图案的激光trabeculoplasty(PLT)的功效和安全不受管束(18公里Hg)intraocular压力(IOP)谁经历了360浥湡？

简介：AIM:Toevaluatethelong-termresponsetothefixedcombinationofdorzolamide/timololinpatientswithprimaryopenangleglaucoma(POAG)andtheadditionofotherintraocularpressure(IOP)loweringmedicationssuchasprostaglandinanalogsandbrimonidine.METHODS:Aretrospective,non-randomized,anddescriptiveclinicalstudywasperformedwith182eyesdiagnosedwithPOAG.Patientsweredividedintothreegroups:agroupwithfixedcombinationofdorzolamide/timololonly,asecondgroupwithprostaglandinanalogsplusfixedcombinationofdorzolamide/timolol,andathirdgroupwiththeadditionofbrimonidinetothesamefixedcombination.IOPdataweregatheredretrospectivelyandthedifferencesbetweengroupswerecalculated.RESULTS:IOPwasreducedsatisfactorilyinallthreegroups;however,aprogressiveIOPreductionwasnotedinthegroupwiththefixedcombinationplusprostaglandinanalogs.Inthisgroup,aprogressive,significantandmorehomogeneousresponseofthereductionwasnotedincomparisonwiththeothergroups.CONCLUSION:IOPreductionwasefficaciousinallthreegroups.TheadditionofprostaglandinanalogsshowedprogressiveIOPreduction,progressiveresponseandabsenceoflong-termdrift.Brimonidinedidnotshowasignificantadditiveeffect.

简介：AIM:Toevaluatetheefficacyandsafetyofanti-vascularendothelialgrowthfactor(VEGF)combinedwithphotodynamictherapy(PDT)versusanti-VEGFmonotherapyforpolypoidalchoroidalvasculopathy(PCV).METHODS:WeconductedaMeta-analysisof9studiestocomparetheefficacyandsafetybetweencombinedtherapyandanti-VEGFmonotherapyforPCV.TheprogramsofRevMan5.3andStata12.0wereusedtoanalyzedata.RESULTS:Thebestcorrectedvisualacuity(BCVA)incombinedtherapygroupweresignificantlybetterthanthoseofanti-VEGFmonotherapygroupat6,24and36mo,withpooledweightedmeansdifferences(WMDs)of0.12(0.06,0.18),0.25(0.12,0.38)and0.28(0.13,0.43),respectively.Thecentralretinalthickness(CRT)reductionsincombinedtherapygroupwerehigherthanthatinantiVEGFmonotherapygroupat1,3,6and9mo,withpooledWMDsof63.90(20.41,107.38),33.47(4.69,62.24),30.57(0.12,60.01)and28.00(2.51,53.49),respectively.Theregressionrateofpolypsincombinedtherapygroupwasmuchhigherthanthatinanti-VEGFmonotherapygroup[RD:0.47(0.26,0.68);P<0.0001].Theadverseeventretinalhemorrhagedidnotdiffersignificantlybetweenthetwogroups.CONCLUSION:OurfindingsclearlydocumentthatantiVEGFcombinedwithPDTisamoreeffectivetherapyforPCVcomparedwithanti-VEGFmonotherapy.Furthermore,combinedtherapydoesnotincreasetheincidenceofretinalhemorrhage.

简介：

简介：AIMTo评估联合反脉管的endothelial生长的功效和安全因素(VEGF)代理人，口头的glucocorticoid，和为有斑点的浮肿的激光光致疑结治疗(我)对.METHODSThis学习包括了的网膜的静脉吸藏(RVO)第二等16个病人与的16只眼睛联系RVO我。病人们开始与口头的泼尼松和一个intravitrealanti-VEGF代理人被对待。二个星期以后，病人们经历了标准激光光致疑结。改正最好的视觉尖酸(BCVA)，中央网膜的厚度(CRT)，和网膜的容器氧化在收到的12mo.RESULTSPatients上被检验1.43

简介：AIM:Tocomparetheefficacyandsafetyofcombinationofranibizumabwithphotodynamictherapy(PDT)vsranibizumabmonotherapyinthetreatmentofage-relatedmaculardegeneration(AMD).METHODS:TheCochraneCentralRegisterofControlledTrials(CENTRAL)intheCochraneLibrary,Pubmed,andEmbaseweresearched.Therewerenolanguageordatarestrictionsinthesearchfortrials.Onlyrandomizedcontrolledtrials(RCTs)wereincluded.MethodologicalqualityoftheliteratureswasevaluatedaccordingtotheJadadScore.RevMan5.2.6softwarewasusedtodothemeta-analysis.RESULTS:Sevenstudieswereincludedinoursystematicreview,amongwhichfourofthemwereincludedinquantitativeanalysis.Theresultshowsthattheranibizumabmonotherapygrouphadabettermeanbestcorrectedvisualacuity(BCVA)changevsbaselineatmonth12comparedwiththatofthecombinationtreatmentgroup,andthestatisticaldifferencewassignificant(WMD,-2.61;95%CI,-5.08to-0.13;P=0.04).However,aftertheremovalofonestudy,thedifferencebetweenthetwogroupsshowednosignificantdifference(WMD,-2.29;95%CI,-4.81to0.23;P=0.07).Meanwhile,nosignificantcentralretinalthickness(CRT)reductionwasfoundinthecombinationtreatmentgroupandtheranibizumabmonotherapygroupat12monthsfollow-up.Nevertheless,thecombinationgrouptendedtohaveagreaterreductioninCRT(WMD,-4.13μm;95%CI,-25.88to17.63,P=0.71).Theproportionofpatientsgainingmorethan3linesatmonth12intheranibizumabgroupwashigherthaninthecombinationgroupandtherewasasignificantdifference(RR,0.72;95%CI,0.54to0.95;P=0.02).Whereastherewasnosignificantdifferencefortheproportionofpatientsgainingmorethan0lineatmonth12betweenthetwogroups(RR,0.93;95%CI,0.76to1.15;P=0.52).Thegeneraltendencyshowsareductioninranibizumabretreatmentnumberinthecombinationtreatmentgroupcomparedwiththeranibizumabmonotherapygroup.Asmajoradverseevents,thedifferencesinthenumberofeyepain,endophthalmitis,hypertensionandarterialt